KDM6A and neoplasm: Studies, including that by Andricovich et al., demonstrate the efficacy of EZH2 inhibitors in both KDM6A-deficient and -proficient PDAC cells, hinting at KDM6A’s broader role in tumor suppression, stem cell maintenance, and developmental processes [36].